In this study, the DNMT inhibitor 5-azacytidine and the HDAC inhibitor butyrate reduced the abundance of cancer stem cells while increasing the overall survival rate in a mouse model. Further analysis indicated that the 5-azacytidine plus butyrate therapy blocked growth-promoting signaling molecules such as RAD51AP1 and SPC25 through the inhibition of chromatin modifiers. These signaling molecules are important in DNA damage repair and kinetochore assembly, and are significantly over expressed in human breast tumor tissues.
Epigenetic modifiers are a promising group of compounds that have seen a large rise in research focus over the past decade. LKT Labs carries a number of DNMT and HDAC inhibitors, in addition to other epigenetic modifiers. A small selection of these popular small molecules are below:
Pathania R, Ramachandran S, et al., Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem-like cells and attenuates mammary tumor growth. Cancer Res. 2016 April.